Enlivex Therapeutics (Israel) Top Management

ENLV Stock  ILA 415.10  4.10  0.98%   
Enlivex Therapeutics employs about 71 people. The company is managed by 18 executives with a total tenure of roughly 88 years, averaging almost 4.0 years of service per executive, having 3.94 employees per reported executive. Analysis of Enlivex Therapeutics' management performance can provide insight into the company performance.
Dror Mevorach  CEO
Chief Executive Officer, Founder, Chief Scientific Officer
Oren Hershkovitz  CEO
Chief Executive Officer
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.

Enlivex Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1888) % which means that it has lost $0.1888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.378) %, meaning that it generated substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Enlivex Therapeutics Workforce Comparison

Enlivex Therapeutics is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 497. Enlivex Therapeutics retains roughly 71.0 in number of employees claiming about 14% of stocks in Biotechnology industry.

Enlivex Therapeutics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Enlivex Therapeutics Price Series Summation is a cross summation of Enlivex Therapeutics price series and its benchmark/peer.

Enlivex Therapeutics Notable Stakeholders

An Enlivex Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enlivex Therapeutics often face trade-offs trying to please all of them. Enlivex Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enlivex Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dror MevorachChief Executive Officer, Founder, Chief Scientific OfficerProfile
Oren HershkovitzChief Executive OfficerProfile
Shachar ShlosbergerChief Financial OfficerProfile
Abraham HavronIndependent DirectorProfile
Gili HartIndependent DirectorProfile
Shai NovikExecutive Chairman of the BoardProfile
Odelia BenShitritHead of Clinical OperationsProfile
Sangwoo LeeDirectorProfile
Baruch HalpertDirectorProfile
Michel HabibDirectorProfile
Shai MBAEx ChairmanProfile
Pr MDFounder OfficerProfile
Veronique AmorBaroukhHead CMCProfile
Shachar CPAChief OfficerProfile
Brian SchwartzDirectorProfile
Bernhard KirschbaumDirectorProfile
Sigal AradDirector HRProfile
Hyun LeeDirectorProfile

About Enlivex Therapeutics Management Performance

The success or failure of an entity such as Enlivex Therapeutics often depends on how effective the management is. Enlivex Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enlivex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enlivex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 50 people.
Please note, the presentation of Enlivex Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enlivex Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enlivex Therapeutics' management manipulating its earnings.

Enlivex Therapeutics Workforce Analysis

Traditionally, organizations such as Enlivex Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enlivex Therapeutics within its industry.

Enlivex Therapeutics Manpower Efficiency

Return on Enlivex Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee203.8K
Net Loss Per Executive803.8K

Complementary Tools for Enlivex Stock analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.